Table 1 Demographic and disease-related characteristics of the population study

No. of cases/controls

81

55

22

17

59

38

Male, n (%)

59 (73)

33 (62)

16 (72)

10 (59)

43 (73)

23 (64)

Age (years)^a

40 ± 13

38 ± 8

41 ± 12

39 ± 9

39 ± 13

37 ± 8

Disease duration (years)^b

4 (0–46)

6.5 (0.2–46)

4 (0–44)

HLA-B27 positive, n (%)

58 (77)

16 (80)

42 (76)

Current smoker, n (%)

38 (47.5)

11 (50)

27 (46)

 AxSpA, n (%)

78 (97.5)

22 (100%)

56 (96)

 AxSpa X-ray positive, n (%)

56 (70)

18 (82)

38 (65)

 AxSpA MRI positive, n (%)

63 (86)

18 (86)

45 (87)

 Peripheral arthritis

17 (21)

6 (27)

11 (19)

 Enthesitis

40 (50)

11 (50)

29 (50)

 IBD

4 (5)

0 (0)

4 (7)

 Uveitis

28 (35)

8 (36)

20 (34)

 Psoriasis

11 (14)

2 (9)

9 (16)

 Baseline CRP, mg/l^a

12.5 ± 17

15 ± 24

12 ± 14

 BASDAI M0^a

49 ± 19

42 ± 18

52 ± 19

 ASDAS M0^a

3 ± 0.9

2.9 ± 0.8

3 ± 1

 NSAIDs, last 3 months, n (%)

64 (80)

19 (86)

45 (78)

 Steroids, last 3 months, n (%)

3 (3.75)

0 (0)

3 (5)

 csDMARDS, last 3 months, n (%)

12 (15)

7 (32)

5 (9)

 Methotrexate, n (%)

5 (42)

2 (29)

3 (60)

 Sulfasalazine, n (%)

7 (58)

5 (71)

2 (40)